Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | MDM4 | O15151 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119530 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL7532853 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29400620 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL30291728 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL120255 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29867802 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL1044856 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL7420121 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29382791 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL1000115 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116773724-A | High performance liquid chromatography for simultaneously detecting fluorenylmethoxycarbonyl-L-isoleucine and four impurity amino acids thereof | 成都郑源生化科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| CN-114874293-B | Cyclic polypeptide compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2025-05-23 | — | — | CN | disclosed |
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-12 | — | — | US | disclosed |
| CN-118843638-A | CRF2 receptor agonists and their use in therapy | 科尔特瑞制药公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4373835-A1 | MACROCYLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-117940445-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116773724-A | High performance liquid chromatography for simultaneously detecting fluorenylmethoxycarbonyl-L-isoleucine and four impurity amino acids thereof | 成都郑源生化科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116773724-A | High performance liquid chromatography for simultaneously detecting fluorenylmethoxycarbonyl-L-isoleucine and four impurity amino acids thereof | 成都郑源生化科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023004240-A1 | MACROCYLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114874293-A | Cyclic polypeptide compounds and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-08-09 | — | — | CN | disclosed |
| WO-2022150768-A1 | YAP-TEAD INHIBITORS AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | TLR2 4837/4885MDM4 1200/4885TP53 88/4885 |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | TLR2 123/4885MDM4 1149/4885TP53 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.